Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum cytoplasmic phenylalanyl-tRNA synthetase (PfcPheRS) is an essential enzyme in the malaria parasite, responsible for catalyzing the attachment of phenylalanine to its corresponding tRNA during protein synthesis. This process is critical for translating genetic information into functional proteins within the parasite. Inhibition of this enzyme by compounds like bicyclic azetidines disrupts protein synthesis and leads to parasite death, making it a validated antimalarial drug target.
Inhibition of phenylalanyl-tRNA synthetase
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum cytoplasmic phenylalanyl-tRNA synthetase (PfcPheRS).